Any current/future new fundraising through debt or equity?

Eris Lifesciences intends to raise around Rs. 1,250 crores through Non-Convertible Debentures (NCDs). The purpose is to repay Commercial Papers (CPs) due in first or second week of June. The company plans to continue deleveraging, targeting a debt-to-EBITDA ratio of less than 2x by September 2025. They plan to repay Rs. 400 crores of debt via internal accruals in FY25 and Rs. 600 crores in the following year. Capex of Rs. 70-80 crores per year is planned for the next two years, mainly for manufacturing units to insource Biocon Injectables portfolio. No new equity fundraising is explicitly ment

Any current/future capex/capital investment/strategic investment?

Capex of Rs. 70 to 80 crores planned annually for FY25 and FY26. Investments focused on setting up manufacturing units at Ahmedabad for insourcing Biocon products, including Insulins, Oncology, and Hormones. Capacity creation is needed for specialized containment units related to these therapies. Emphasis on converting the Biocon Injectables portfolio in-house. Investment in strengthening the production footprint to support export of oral solid dose forms and leverage Swiss Parenterals' channel. Continued investment in in-house manufacturing sites (Guwahati and Ahmedabad), which currently acco

Future growth expectations in sales/revenue/volumes?

Eris Lifesciences expects organic revenue growth of 12% to 15% in Domestic Branded Formulations for FY25, continuing the momentum seen with 15% organic growth in Q4 FY24. The company is well-positioned for a diversified therapy mix driving this growth, supported by strong Diabetes portfolio including Linagliptin, Dapagliflozin combinations, and Vildagliptin in the generic space. Over 20 first-in-market launches from their own R&D pipeline are anticipated, along with integration benefits from acquisitions like Biocon Injectables and Swiss Parenterals. Expansion of new therapies such as De

Future growth expectations in earnings/operating earnings/profits/EPS?

Eris Lifesciences expects sustained organic revenue growth of 12%–14% in Domestic Branded Formulations for FY25, following a 9%–10% growth in FY24. EBITDA margins for Domestic Formulations are expected to maintain around 36%. Adjusted consolidated EBITDA for FY24 was Rs. 713 crores (36% margin), with adjusted PAT at Rs. 432 crores (22% margin), showing 33% and 16% growth YoY, respectively. Earnings Per Share (EPS) for FY24 was Rs. 29 (6% growth YoY) with cash EPS at Rs. 38 (14% growth). Margin expansion and earnings growth are anticipated as integration and normalization progress, especially i

Current/ Expected Orderbook/ Pending Orders?

No explicit mention of a current or expected order book or pending orders in the provided transcript. Amit Bakshi mentioned new product launches in the pipeline: - Two products launched this fiscal (Feb-Mar): Gliclazide with Sitagliptin combination. - Awaiting approval and additional bioequivalence (BE) study for a third triple drug. - Marketing authorization obtained for Dapagliflozin and Metoprolol; awaiting final licenses. - Next product in line: Dapagliflozin with Bisoprolol, targeting heart failure. - Expected launches mainly in Q1, with quieter Q2 and pickup in Q3. R&D pipel

ERIS Lifesciences LtdQ4 FY24Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,190P/E: 26.6Market Cap: ₹17.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Eris Lifesciences expects organic revenue growth of 12% to 15% in Domestic Branded Formulations for FY25, continuing the momentum seen with 15% organic growth in Q4 FY24.
The company is well-positioned for a diversified therapy mix driving this growth, supported by strong Diabetes portfolio including Linagliptin, Dapagliflozin combinations, and Vildagliptin in the generic space.
Over 20 first-in-market launches from their own R&D pipeline are anticipated, along with integration benefits from acquisitions like Biocon Injectables and Swiss Parenterals.
Expansion of new therapies such as Dermatology, Oncology, Nephrology, Immunology, and Insulins is expected to further contribute to secular growth.
Manufacturing insourcing and capacity additions (Ahmedabad plant) are planned to support revenue scaling and margin enhancement.
Growth in large brands and new product launches positions the company to continue outpacing market growth.

Margin guidance

Category 3

Eris Lifesciences expects sustained organic revenue growth of 12%–14% in Domestic Branded Formulations for FY25, following a 9%–10% growth in FY24.
EBITDA margins for Domestic Formulations are expected to maintain around 36%.
Adjusted consolidated EBITDA for FY24 was Rs. 713 crores (36% margin), with adjusted PAT at Rs. 432 crores (22% margin), showing 33% and 16% growth YoY, respectively.
Earnings Per Share (EPS) for FY24 was Rs. 29 (6% growth YoY) with cash EPS at Rs. 38 (14% growth).
Margin expansion and earnings growth are anticipated as integration and normalization progress, especially in newer therapies like Dermatology, Oncology, Insulins, and Nephrology.
Operating cash flow conversion is strong at 70%–75% of EBITDA, supporting debt reduction and margin stability.
Breakeven achieved for MJ Biopharm; run rate improving, indicating profitability momentum.

See what ERIS Lifesciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Eris Lifesciences intends to raise around Rs. 1,250 crores through Non-Convertible Debentures (NCDs).
The purpose is to repay Commercial Papers (CPs) due in first or second week of June.
The company plans to continue deleveraging, targeting a debt-to-EBITDA ratio of less than 2x by September 2025.
They plan to repay Rs. 400 crores of debt via internal accruals in FY25 and Rs. 600 crores in the following year.
Capex of Rs. 70-80 crores per year is planned for the next two years, mainly for manufacturing units to insource Biocon Injectables portfolio.
No new equity fundraising is explicitly mentioned in the disclosed sections.

Order book

No explicit mention of a current or expected order book or pending orders in the provided transcript.
Amit Bakshi mentioned new product launches in the pipeline:
- Two products launched this fiscal (Feb-Mar): Gliclazide with Sitagliptin combination.
- Awaiting approval and additional bioequivalence (BE) study for a third triple drug.
- Marketing authorization obtained for Dapagliflozin and Metoprolol; awaiting final licenses.
- Next product in line: Dapagliflozin with Bisoprolol, targeting heart failure.
- Expected launches mainly in Q1, with quieter Q2 and pickup in Q3.
R&D pipeline includes over 20 first-in-market launches with good visibility post Q1.
No direct figures or value of order book mentioned.

See what ERIS Lifesciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex of Rs. 70 to 80 crores planned annually for FY25 and FY26.
Investments focused on setting up manufacturing units at Ahmedabad for insourcing Biocon products, including Insulins, Oncology, and Hormones.
Capacity creation is needed for specialized containment units related to these therapies.
Emphasis on converting the Biocon Injectables portfolio in-house.
Investment in strengthening the production footprint to support export of oral solid dose forms and leverage Swiss Parenterals' channel.
Continued investment in in-house manufacturing sites (Guwahati and Ahmedabad), which currently account for around 60% of Domestic Branded Formulations revenue.
Strategic investment directed at business integration and new product launches, with over 20 first-in-market launches expected from the R&D pipeline.

Track ERIS Lifesciences Ltd — get its next earnings analysis in your feed

How does ERIS Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisERIS Lifesciences Ltd

Rev 3Mar 3

See where ERIS Lifesciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does ERIS Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare ERIS Lifesciences Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What ERIS Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

ERIS Lifesciences Ltd Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does ERIS Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What ERIS Lifesciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season